准KRAS突变:编排癌症演变和治疗挑战
Khalil Choucair1, Hafsa Imtiaz1, Md Hafiz Uddin1
1Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA.
Signal transduction and targeted therapy
|November 27, 2025
概括
针对癌症中的KRAS突变显示出希望,但目前对KRAS G12C的治疗方法的疗效和耐药性有限. 新的策略正在探索各种KRAS突变的组合疗法,包括胰腺癌.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 激活KRAS突变在固体瘤中普遍存在,从历史上来看,这对治疗构成了挑战.
- 经批准的KRASG12C抑制剂提供适度的反应率,并与耐药性相关.
- 在胰腺癌中常见的非G12C KRAS 突变缺乏有效的向治疗.
研究的目的:
- 审查RAS信号通路和针对瘤性RAS的当前治疗策略.
- 讨论新兴的组合疗法和KRAS抑制的新方法.
- 分析耐药性机制和开发针对KRAS的治疗方法的临床试验状态.
主要方法:
- 关于RAS通路信号和KRAS突变驱动癌症的文献综述.
- 对KRAS抑制的当前和试验性治疗策略的分析.
- 检查耐药性机制及其对治疗疗效的影响.
主要成果:
- 两种KRASG12C抑制剂已获得批准,但有效性有限,导致耐药性.
- 针对其他KRAS突变存在重大未满足的需求,特别是在胰腺癌中.
- 了解RAS信号和瘤微环境的进步使新的组合疗法成为可能.
结论:
- 尽管取得了进展,但要实现对KRAS突变癌症的治疗,需要克服耐药性和解决多种突变.
- 新型组合疗法和对抗性机制的更深入的理解对于推进KRAS向治疗至关重要.
- 目前正在进行的临床试验正在评估新的策略,以改善KRAS驱动恶性瘤患者的治疗结果.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
18.5K
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
11.1K
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
The Ras Gene
7.0K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
7.0K
Cancer
53.4K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
53.4K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Adaptive Mechanisms in Cancer Cells
6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
